Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Daiichi Sankyo
Fuji
Healthtrust
Cerilliant
Accenture
QuintilesIMS
Moodys
Cantor Fitzgerald

Generated: October 23, 2017

DrugPatentWatch Database Preview

PREVACID Drug Profile

« Back to Dashboard

Which patents cover Prevacid, and when can generic versions of Prevacid launch?

Prevacid is a drug marketed by Takeda Pharms Usa, Takeda Pharms Na, and Glaxosmithkline Cons. and is included in six NDAs. There are five patents protecting this drug and two Paragraph IV challenges.

This drug has sixty-three patent family members in nineteen countries and three supplementary protection certificates in two countries.

The generic ingredient in PREVACID is lansoprazole; naproxen. There are fifty-four drug master file entries for this compound. Additional details are available on the lansoprazole; naproxen profile page.

Summary for Tradename: PREVACID

US Patents:4
Applicants:3
NDAs:6
Suppliers / Packagers: see list9
Bulk Api Vendors: see list81
Clinical Trials: see list22
Patent Applications: see list4,035
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:PREVACID at DailyMed

Pharmacology for Tradename: PREVACID

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa
PREVACID
lansoprazole
CAPSULE, DELAYED REL PELLETS;ORAL020406-001May 10, 1995ABRXYesNo► Subscribe► Subscribe► Subscribe
Takeda Pharms Usa
PREVACID
lansoprazole
TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL021428-002Aug 30, 2002ABRXYesYes► Subscribe► SubscribeY► Subscribe
Takeda Pharms Usa
PREVACID
lansoprazole
TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL021428-001Aug 30, 2002ABRXYesNo► Subscribe► SubscribeY► Subscribe
Takeda Pharms Na
PREVACID
lansoprazole
FOR SUSPENSION, DELAYED RELEASE;ORAL021281-002May 3, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe
Takeda Pharms Usa
PREVACID
lansoprazole
TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL021428-002Aug 30, 2002ABRXYesYes► Subscribe► SubscribeY► Subscribe
Takeda Pharms Na
PREVACID NAPRAPAC 375 (COPACKAGED)
lansoprazole; naproxen
CAPSULE, DELAYED REL PELLETS, TABLET;ORAL021507-003Nov 14, 2003DISCNNoNo► Subscribe► Subscribe► Subscribe
Takeda Pharms Na
PREVACID IV
lansoprazole
INJECTABLE;INTRAVENOUS021566-001May 27, 2004DISCNYesNo► Subscribe► SubscribeY► Subscribe
Takeda Pharms Usa
PREVACID
lansoprazole
CAPSULE, DELAYED REL PELLETS;ORAL020406-002May 10, 1995ABRXYesYes► Subscribe► Subscribe► Subscribe
Takeda Pharms Usa
PREVACID
lansoprazole
TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL021428-001Aug 30, 2002ABRXYesNo► Subscribe► SubscribeY► Subscribe
Takeda Pharms Usa
PREVACID
lansoprazole
TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL021428-001Aug 30, 2002ABRXYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: PREVACID

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms Usa
PREVACID
lansoprazole
TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL021428-001Aug 30, 2002► Subscribe► Subscribe
Takeda Pharms Na
PREVACID
lansoprazole
FOR SUSPENSION, DELAYED RELEASE;ORAL021281-002May 3, 2001► Subscribe► Subscribe
Takeda Pharms Na
PREVACID
lansoprazole
FOR SUSPENSION, DELAYED RELEASE;ORAL021281-002May 3, 2001► Subscribe► Subscribe
Takeda Pharms Na
PREVACID
lansoprazole
FOR SUSPENSION, DELAYED RELEASE;ORAL021281-001May 3, 2001► Subscribe► Subscribe
Takeda Pharms Usa
PREVACID
lansoprazole
TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL021428-001Aug 30, 2002► Subscribe► Subscribe
Takeda Pharms Usa
PREVACID
lansoprazole
TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL021428-001Aug 30, 2002► Subscribe► Subscribe
Takeda Pharms Usa
PREVACID
lansoprazole
CAPSULE, DELAYED REL PELLETS;ORAL020406-001May 10, 1995► Subscribe► Subscribe
Takeda Pharms Na
PREVACID
lansoprazole
FOR SUSPENSION, DELAYED RELEASE;ORAL021281-001May 3, 2001► Subscribe► Subscribe
Takeda Pharms Usa
PREVACID
lansoprazole
TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL021428-002Aug 30, 2002► Subscribe► Subscribe
Takeda Pharms Usa
PREVACID
lansoprazole
TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL021428-002Aug 30, 2002► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for PREVACID

Drugname Dosage Strength RLD Submissiondate
lansoprazoleDelayed-release Orally Disinte15 mg and 30 mgPrevacid12/27/2006
lansoprazoleDelayed-release Pellets/Capsul15 mg and 30 mgPrevacid12/5/2005

Non-Orange Book Patents for Tradename: PREVACID

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,070,805Rapidly disintegrable solid preparation► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: PREVACID

Country Document Number Estimated Expiration
Argentina019935► Subscribe
Hong Kong1096021► Subscribe
Japan3746167► Subscribe
China1311669► Subscribe
Canada2323680► Subscribe
Portugal1561458► Subscribe
World Intellectual Property Organization (WIPO)0006126► Subscribe
Slovenia1100469► Subscribe
Argentina080436► Subscribe
Taiwan585786► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: PREVACID

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
14/008Ireland► SubscribePRODUCT NAME: DEXLANSOPRAZOLE OR A SALT THEREOF; NAT REGISTRATION NO/DATE: PA1864/001/001-002;PA1864/002/001-002 20131125; FIRST REGISTRATION NO/DATE: 47911 47912 47913 47914 20130919
C0021Belgium► SubscribePRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
C0021Belgium► SubscribePRODUCT NAME: LANSOPRAZOLE; NAT. REG.: 150 S 539 F 4 19921119; FIRST REG.: FR 333 412.1 19901211
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
UBS
Novartis
Johnson and Johnson
Cipla
Harvard Business School
Healthtrust
Covington
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot